Company has profit for the 2nd quarter ended June 30, 2019 in the amount of Baht 4.21 million (profit per share Baht 0.42), compared to the same quarter of last year which had loss of Baht 2.82 million
Committee Meeting without the attendance of the connected director had considered and agreed that this transaction is under normal commercial terms and price comparing with other service provider in the same
below: From the Consolidated Financial Statements for the second quarter of 2019, for the three- month period ended June 30, 2019, the Company had operating profit of the equity holders of THB 8.07
the period that US Federal Reserve would cut the interest rates. However, on 7 August 2019, the Bank of Thailand had announced the policy to cut interest rate which could expect Thai baht to become
directors who have interests and/or directors who are connected persons precluded themselves from meeting participation and voting, had consciously considered and has approved the entering into the related
5,547,902.42 Baht or 62.08% from the cost of land in the new project. In addition, the company had higher selling and administrative expenses. As a result, in Q1/2018, there was the net loss amount 2,836,460.81
products, especially products which started selling in 2017 and had full recognition in 2018. The product category with highest revenue increased was facial skincare products with its revenue increased
associated company 141.99 million baht while it had only 71.35 million baht in 2017. The details are as follows: Unit : Million baht 2018 2017 Chiangmai Ram Hospital Company Limited 33.47 25.64 Rangsiphan
affected from the government stimulus and provides general provision to support the new accounting policy change. Financial Position Overview As of the end of the second quarter of 2018, the Company had
the connected director had considered and agreed that this transaction is under normal commercial terms and price comparing with other service provider in the same industry. The Audit Committee resolved